IL18 and achalasia-alacrima syndrome: Many clinical and experimental studies have demonstrated elevated levels of NLRP3 inflammasome effector mediators such as IL-1β and IL-18 in AAAs [25,26] with the major sources of the increased expression of these effectors being aortic macrophages and vascular smooth muscle cells.